Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
Background: Systemic corticosteroids (SCs) are associated with reduced survival in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) monotherapy. However, the current first-line standard of care usually involves combined chemotherapy (CT) and ICIs,...
Saved in:
Main Authors: | Amytis Roboubi, Eric Wasielewski, Soraya Bordier, Amélie Turlotte, Geoffrey Pavaut, Arnaud Scherpereel, Alexis Cortot, Clément Gauvain |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359251318160 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01) -
Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01) -
Pembrolizumab-related pneumonitis in a patient with COVID-19 infection
by: Venkataganesan Ponnalagu, et al.
Published: (2023-07-01) -
Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
by: Amarilla Barcsay-Veres, et al.
Published: (2025-02-01) -
Antenatal corticosteroids in Singapore: a clinical and scientific assessment
by: Arundhati Gosavi, et al.
Published: (2024-09-01)